Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, R. A. Velichinskii, Randy W. Lesh, et al.
Advances in Therapy (2019) Vol. 36, Iss. 10, pp. 2638-2678
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

G-quadruplexes: a promising target for cancer therapy
Nils Kosiol, Stefan Juranek, Peter Brossart, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 372
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Sehhoon Park, Chan‐Young Ock, Hyojin Kim, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 17, pp. 1916-1928
Open Access | Times Cited: 168
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas, Ghaneya Al‐Khadairi, Julie Decock
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 130
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 101
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 57
Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells
Ce Luo, Rui Zhang, Rui Guo, et al.
Immunity (2025)
Closed Access | Times Cited: 2
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Bin Zhao, Hong Zhao, Jiaxin Zhao
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 127
Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116
Molecular subtypes and precision treatment of triple-negative breast cancer
Shen Zhao, Wen‐Jia Zuo, Zhi‐Ming Shao, et al.
Annals of Translational Medicine (2020) Vol. 8, Iss. 7, pp. 499-499
Open Access | Times Cited: 103
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 97
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Ying Li, Zhijun Zhan, Xuemin Yin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 80
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Laura Boyero, Amparo Sánchez-Gastaldo, Miriam Alonso, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3729-3729
Open Access | Times Cited: 77
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
Selene Ottonello, Carlo Genova, Irene Cossu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 75
PD−L1 immunostaining: what pathologists need to know
Mohammed Akhtar, Sameera Rashid, Issam Al‐Bozom
Diagnostic Pathology (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 71
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review
Daniele Presti, Filippo Gustavo Dall’Olio, Benjamin Besse, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 177, pp. 103773-103773
Closed Access | Times Cited: 50
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Maryland Franklin, Suso Platero, Kamal S. Saini, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003231-e003231
Open Access | Times Cited: 38
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 38
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
Yue Wang, Shikun Zhou, Yan Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
Imaging immune checkpoint networks in cancer tissues with supermultiplexed SERS nanoprobes
Jin Li, Fugang Liu, Xinyuan Bi, et al.
Biomaterials (2023) Vol. 302, pp. 122327-122327
Closed Access | Times Cited: 23
Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Manman Liu, Duo Jin, Wenxin Yu, et al.
Advanced Science (2024) Vol. 11, Iss. 20
Open Access | Times Cited: 13
Hybrid Cellular Nanovesicles Block PD‐L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy
Chenchen Zhao, Yuanwei Pan, Lujie Liu, et al.
Small (2024) Vol. 20, Iss. 31
Closed Access | Times Cited: 9
Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans
Deborah W. Knapp, Deepika Dhawan, José A. Ramos‐Vara, et al.
Frontiers in Oncology (2020) Vol. 9
Open Access | Times Cited: 69
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, et al.
Seminars in Cancer Biology (2020) Vol. 79, pp. 18-43
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top